Tuesday, October 2, 2018 Daily Archives

Novartis buys 9% stake in Chinese Kymriah manufacturing partner

by

Novartis has paid $40 million for a 9% stake in Cellular Biomedicine Group (CBMG), a Shanghai-based firm which will manufacture CAR-T cell therapy Kymriah for the China market. Under terms of the deal, CBMG will take responsibility for the manufacture of the chimeric antigen receptor (CAR) T-cell therapy Kymriah (tisagenlecleucel) from its facility in Shanghai, China, on behalf of Novartis entity Beijing Novartis Pharma for supply in China. “Aligned with our global supply and regulatory strategy, Novartis actively has been…

October 2, 2018

The POD couple: Pall and G-CON team on modular cleanrooms

by

Pall’s continuous bioprocessing technologies will be incorporated into G-CON’s prefabricated ‘POD’ cleanroom units in efforts to address current capacity constraint, CAPEX deferment, and cost predictability. G-CON’s PODs are mobile cleanroom units, which include integrated process piping and heating and air conditioning (HVAC) system. A collaboration with bioprocessing vendor Pall Biotech will bring its continuous bioprocessing and viral vector production designs, including automation and utility supplies, to the units. The partnership sets out to solve three needs: contract development and manufacturing…

October 2, 2018